新型冠状病毒肺炎治疗靶点与潜在药物的研究进展
Recent advances of therapeutic targets and potential drugs of COVID-19.
作者信息
Zhang W, Zhang P, Wang G, Cheng W, Chen J, Zhang X
机构信息
Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; Children's Hospital Affiliated of Zhengzhou University; Department of Pediatric Oncology Surgery, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China;, Email:
Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
出版信息
Pharmazie. 2020 May 1;75(5):161-163. doi: 10.1691/ph.2020.0431.
Since December 2019, numerous cases of coronavirus disease 2019 (COVID-19) caused by the infection of the novel coronavirus (2019-nCoV) have been confirmed in Wuhan, China. The outbreak of 2019-nCoV in China embodied a significant and urgent threat to global health. 2019-nCoV was a new, highly contagious coronavirus discovered following the outbreak of SARS coronavirus (SARS-CoV) and MERS coronavirus (MERS-CoV). The novel coronavirus can cause severe respiratory disease and even death. However, no specific therapeutic drugs have been developed clinically thus far. This article examines the potential of therapeutic drugs by assessing the structure of 2019-nCoV, its mechanism in invading host cells, and the anti-viral mechanism of the human autoimmune system. We also review the latest research regarding the progress of potential therapeutic drugs and provide references for new drug developments of COVID-19.
自2019年12月以来，中国武汉已确诊多例由新型冠状病毒（2019-nCoV）感染引起的2019冠状病毒病（COVID-19）。2019-nCoV在中国的爆发对全球健康构成了重大且紧迫的威胁。2019-nCoV是继严重急性呼吸综合征冠状病毒（SARS-CoV）和中东呼吸综合征冠状病毒（MERS-CoV）爆发后发现的一种新的、高传染性的冠状病毒。这种新型冠状病毒可导致严重的呼吸道疾病甚至死亡。然而，迄今为止临床上尚未研发出特异性治疗药物。本文通过评估2019-nCoV的结构、其侵入宿主细胞的机制以及人类自身免疫系统的抗病毒机制，探讨治疗药物的潜力。我们还综述了关于潜在治疗药物进展的最新研究，并为COVID-19的新药研发提供参考。
Zotero 插件